Pre-treatment EEG signal variability is associated with treatment success in depression

被引:29
|
作者
Jaworska, Natalia [1 ]
Wang, Hongye [2 ]
Smith, Dylan M. [3 ]
Blier, Pierre [1 ]
Knott, Verner [1 ]
Protzner, Andrea B. [2 ,4 ]
机构
[1] Univ Ottawa, Inst Mental Hlth Res, Ottawa, ON, Canada
[2] Univ Calgary, Dept Psychol, 2500 Univ Dr NW, Calgary, AB T2N 1N4, Canada
[3] Concordia Univ, Ctr Studies Behav Neurobiol, Montreal, PQ, Canada
[4] Univ Calgary, Hotchkiss Brain Inst, Calgary, AB, Canada
关键词
Depression; Treatment; Response; Multi-scale entropy (MSE); Electroencephalography (EEG); Signal variability; Spectral power density (SPD); STATE FUNCTIONAL-MRI; DEFAULT-MODE; ALPHA POWER; CONNECTIVITY; COMPLEXITY; ENTROPY; DISORDER; NETWORK; SCALE; SYNCHRONIZATION;
D O I
10.1016/j.nicl.2017.10.035
中图分类号
R445 [影像诊断学];
学科分类号
100207 ;
摘要
Background: Previous work suggests that major depressive disorder (MDD) is associated with disturbances in global connectivity among brain regions, as well as local connectivity within regions. However, the relative importance of these global versus local changes for successful antidepressant treatment is unknown. We used multiscale entropy (MSE), a measure of brain signal variability, to examine how the propensity for local (fine scale MSE) versus global (coarse scale MSE) neural processing measured prior to antidepressant treatment is related to subsequent treatment response. Methods: We collected resting-state EEG activity during eyes-open and closed conditions from unmedicated individuals with MDD prior to antidepressant pharmacotherapy (N = 36) as well as from non-depressed controls (N = 36). Treatment response was assessed after 12 weeks of treatment using the Montgomery-Asberg Depression Rating Scale (MADRS), at which time participants with MDD were characterized as either responders (= 50% MADRS decrease) or non-responders. MSE was calculated from baseline EEG, and compared between controls, future treatment responders and non-responders. Putative interactions with the well-documented age effect on signal variability (increased reliance on local neural communication with increasing age, indexed by greater finer-scale variability) were assessed. Results: Only in responders, we found that reduced MSE at fine temporal scales (especially fronto-centrally) and increased MSE diffusely at coarser temporal scales was related to the magnitude of the antidepressant response. In controls and MDD non-responders, but not MDD responders, there was an increase in MSE with age at fine temporal scales and a decrease in MSE with age at coarse temporal scales. Conclusion: Our results suggest that an increased propensity toward global processing, indexed by greater MSE at coarser timescales, at baseline appears to facilitate eventual antidepressant treatment response.
引用
收藏
页码:368 / 377
页数:10
相关论文
共 50 条
  • [31] Pre-treatment symptom cluster in breast cancer patients is associated with worse sleep, fatigue and depression during chemotherapy
    Liu, Lianqi
    Fiorentino, Lavinia
    Natarajan, Loki
    Parker, Barbara A.
    Mills, Paul J.
    Sadler, Georgia Robins
    Dimsdale, Joel E.
    Rissling, Michelle
    He, Feng
    Ancoli-Israel, Sonia
    PSYCHO-ONCOLOGY, 2009, 18 (02) : 187 - 194
  • [32] Evaluation of pre-treatment verification for hyperthermia treatment plans
    Marder, D.
    Brandli, N.
    VanStam, G.
    Lutters, G.
    RADIOTHERAPY AND ONCOLOGY, 2016, 119 : S919 - S920
  • [33] Impact of pre-treatment technologies on soil aquifer treatment
    Besancon, A.
    Pidou, M.
    Jeffrey, P.
    Jefferson, B.
    Le Corre, K. S.
    JOURNAL OF WATER REUSE AND DESALINATION, 2017, 7 (01): : 1 - 10
  • [34] Pre-treatment antibodies to infliximab and adalimumab are common but are not associated with anti-TNF treatment failure
    Nice, R.
    Goodhand, J. R.
    Kennedy, N.
    Ahmad, T.
    Winyard, P.
    McDonald, T. J.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I256 - I256
  • [35] Pre-treatment plasma proteomic markers associated with survival in oesophageal cancer
    Kelly, P.
    Paulin, F.
    Lamont, D.
    Baker, L.
    Clearly, S.
    Exon, D.
    Thompson, A.
    BRITISH JOURNAL OF CANCER, 2012, 106 (05) : 955 - 961
  • [36] Pre-treatment plasma proteomic markers associated with survival in oesophageal cancer
    P Kelly
    F Paulin
    D Lamont
    L Baker
    S Clearly
    D Exon
    A Thompson
    British Journal of Cancer, 2012, 106 : 955 - 961
  • [37] Escitalopram Response is Associated With Pre-Treatment Neuraland Clinical Correlates of Anhedonia
    Dunlop, Katharine
    Rizvi, Sakina
    Leng, Xiamen
    Hassel, Stefanie
    Strother, Stephen
    Lam, Raymond
    Milev, Roumen
    Rotzinger, Susan
    Foster, Jane
    Frey, Benicio
    Parikh, Sagar
    Soares, Claudio
    Uher, Rudolf
    Turecki, Gustavo
    MacQueen, Glenda
    Downar, Jonathan
    Kennedy, Sidney
    NEUROPSYCHOPHARMACOLOGY, 2018, 43 : S127 - S128
  • [38] Pre-Treatment and Post-Treatment Anxiety, Depression, Sleep and Sexual Function Levels in Patients with Breast Cancer
    Izci, Filiz
    Ozdem, Gozdem
    Ilgun, Ahmet Serkan
    Agacayak, Filiz
    Duymaz, Tomris
    Erdogan, Zeynep
    Alco, Gul
    Elbuken, Filiz
    Ozturk, Alper
    Ordu, Cetin
    Atesal, Kubra Ceren
    Dogan, Ozge Ipek
    Aktepe, Fatma
    Ozmen, Vahit
    EUROPEAN JOURNAL OF BREAST HEALTH, 2020, 16 (03) : 219 - 225
  • [39] Wall cleanings for pre-treatment on EAST
    Li Jia-Hong
    Hu Jian-Sheng
    Wang Xiao-Ming
    Yu Yao-Wei
    Wu Jin-Hua
    Chen Yue
    Wang Hou-Yin
    ACTA PHYSICA SINICA, 2012, 61 (20)
  • [40] Desalination: Developments in pre-treatment technology
    Bennett, Anthony
    FILTRATION & SEPARATION, 2012, 49 (05): : 16 - +